AREV Appoints Dr. Roscoe Moore to Join the Advisory Board
VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) — AREV NANOTEC BRANDS INC. (CSE: AREV) (OTC: AREVF) (“AREV Brands”) is pleased to announce the appointment of Dr. Roscoe Moore DVM, MPH, PhD, Former Assistant United States Surgeon General to the Scientific Advisory Board for AREV Nanotec Brands Inc, to provide strategic planning for AREV drug discovery planning, as a Senior Scientific Advisor.
Dr. Moore is a Board member of the Board of Advisors and the Board of Directors of the Global Virus Network at the Institute of Human Virology (IHV), University of Maryland Medical Center, According to the National Science Foundation, UMB’s budget for research and development in 2019 was $1.1 billion, ranking it 14th overall in the nation and 8th among all public institutions.The IHV is the first research institute in the U.S. to link basic science, population studies and clinical trials in an effort to develop new vaccines and treatments. The IHV currently retains more than 300 employees include more than 80 faculty whose research efforts are focused on the area of chronic human viral infection and disease, and contributing to research on pandemic pathogens, ranging from COVID-19 to HIV.Dr. Roscoe M. Moore Jr. served with the United States Department of Health and Human Services (“HHS”) and was responsible for the last twelve years of his career for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs resource challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service entering with the U.S. National Institutes of Health and rising to the rank of Assistant United States Surgeon General within the Immediate Office of the Secretary, HHS. Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (“CDC”).He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration, before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. Dr. Moore has conducted clinical research on infectious diseases, has evaluated the safety and effectiveness of medical devices, and has conducted relevant epidemiological research on the utilization experience and human health effects of medical devices and radiation. Dr. Moore served on the Fogarty International Center Advisory Board of Directors, NIH from 2009 to 2013. He served on the Alumni Board of Directors, School of Public Health, University of Michigan from 1987 to 1993. Dr. Moore served on the Dean’s Alumni Council, Bloomberg School of Public Health, at Johns Hopkins University from 1998 to 2002. He has also served as an Affiliate Associate Professor of Environmental Health for the University of Washington, Seattle from 1994 to 2003 and as an Adjunct Professor of Epidemiology, for the Medical University of Southern Africa, Pretoria, South Africa from 1999 to 2002. He served on the Board of Directors for the Africa Center for Health and Human Security, at George Washington University from 2006 to 2009.AREV Nanotech’s CEO, Mike Withrow commented “We’re very excited to welcome Dr. Moore to the AREV Nanotec Scientific Advisory Board. Dr Moore’s introduction to AREV Nanotech represents the emerging discovery opportunities being presented to the company now, as we pursue a range of pre-clinical investigations intended to identify antiviral phytomedicinal chemistries. This exciting focus is coming to also focusing on our emerging human and veterinary nutrition initiatives to improve global public health. Our intent to become a global leader in contributing to innovative therapeutic sustainable interventions that will be transformative to medicine and healthcare including our initial antiviral discovery program, AREV’s human and veterinary nutrition product development and our competitive extraction science platform innovations, all of which are presenting very attractive opportunities to our investors and collaborators.”Dr. Moore commented, “AREV Nanotech is developing a range of integrated extraction technologies that will help mature phytomedicinal discovery and advance promising therapies from bench to bedside. The necessity of advancing new innovations in discovery and subsequent therapeutics to address challenges in global public health. The current co-intersection of global pandemics emphasizes the value of companies like AREV which are focusing on the innovations to expand our current pharmacopeia to cultivate subsequent generations of phytomedicinal discovery.”The company has issued 250,000 stock options to Directors, Officers and Consultants of the Company at a price of $0.31 for a period of 5 years from the issued date. These options will vest immediately.For further information, contact Mike Withrow, mike@AREVBrands.com 778-929-6536. For more information visit arevnanotec.comOn behalf of the Board,Mike Withrow
CEO & DirectorAbout AREV NanoTec Inc.
AREV NanoTec Brands Inc. (“AREV”) is an early stage publicly traded life science development enterprise focused on phytomedicinal extraction of novel therapeutic approaches to infectious diseases and subsequent comorbidities via its proprietary extraction systems to identify promising small molecules that present novel mechanisms of action in human and veterinary science.AREV’s model is to toll process extraction of targeted essential and functional oils and license its formulations to Licensed Producers in Canada. The company utilizes toll processors in foreign countries to encapsulate and package its formulations that can be sold in traditional distribution channels and online.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Dr. Moore is a Board member of the Board of Advisors and the Board of Directors of the Global Virus Network at the Institute of Human Virology (IHV), University of Maryland Medical Center, According to the National Science Foundation, UMB’s budget for research and development in 2019 was $1.1 billion, ranking it 14th overall in the nation and 8th among all public institutions.The IHV is the first research institute in the U.S. to link basic science, population studies and clinical trials in an effort to develop new vaccines and treatments. The IHV currently retains more than 300 employees include more than 80 faculty whose research efforts are focused on the area of chronic human viral infection and disease, and contributing to research on pandemic pathogens, ranging from COVID-19 to HIV.Dr. Roscoe M. Moore Jr. served with the United States Department of Health and Human Services (“HHS”) and was responsible for the last twelve years of his career for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs resource challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service entering with the U.S. National Institutes of Health and rising to the rank of Assistant United States Surgeon General within the Immediate Office of the Secretary, HHS. Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (“CDC”).He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration, before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. Dr. Moore has conducted clinical research on infectious diseases, has evaluated the safety and effectiveness of medical devices, and has conducted relevant epidemiological research on the utilization experience and human health effects of medical devices and radiation. Dr. Moore served on the Fogarty International Center Advisory Board of Directors, NIH from 2009 to 2013. He served on the Alumni Board of Directors, School of Public Health, University of Michigan from 1987 to 1993. Dr. Moore served on the Dean’s Alumni Council, Bloomberg School of Public Health, at Johns Hopkins University from 1998 to 2002. He has also served as an Affiliate Associate Professor of Environmental Health for the University of Washington, Seattle from 1994 to 2003 and as an Adjunct Professor of Epidemiology, for the Medical University of Southern Africa, Pretoria, South Africa from 1999 to 2002. He served on the Board of Directors for the Africa Center for Health and Human Security, at George Washington University from 2006 to 2009.AREV Nanotech’s CEO, Mike Withrow commented “We’re very excited to welcome Dr. Moore to the AREV Nanotec Scientific Advisory Board. Dr Moore’s introduction to AREV Nanotech represents the emerging discovery opportunities being presented to the company now, as we pursue a range of pre-clinical investigations intended to identify antiviral phytomedicinal chemistries. This exciting focus is coming to also focusing on our emerging human and veterinary nutrition initiatives to improve global public health. Our intent to become a global leader in contributing to innovative therapeutic sustainable interventions that will be transformative to medicine and healthcare including our initial antiviral discovery program, AREV’s human and veterinary nutrition product development and our competitive extraction science platform innovations, all of which are presenting very attractive opportunities to our investors and collaborators.”Dr. Moore commented, “AREV Nanotech is developing a range of integrated extraction technologies that will help mature phytomedicinal discovery and advance promising therapies from bench to bedside. The necessity of advancing new innovations in discovery and subsequent therapeutics to address challenges in global public health. The current co-intersection of global pandemics emphasizes the value of companies like AREV which are focusing on the innovations to expand our current pharmacopeia to cultivate subsequent generations of phytomedicinal discovery.”The company has issued 250,000 stock options to Directors, Officers and Consultants of the Company at a price of $0.31 for a period of 5 years from the issued date. These options will vest immediately.For further information, contact Mike Withrow, mike@AREVBrands.com 778-929-6536. For more information visit arevnanotec.comOn behalf of the Board,Mike Withrow
CEO & DirectorAbout AREV NanoTec Inc.
AREV NanoTec Brands Inc. (“AREV”) is an early stage publicly traded life science development enterprise focused on phytomedicinal extraction of novel therapeutic approaches to infectious diseases and subsequent comorbidities via its proprietary extraction systems to identify promising small molecules that present novel mechanisms of action in human and veterinary science.AREV’s model is to toll process extraction of targeted essential and functional oils and license its formulations to Licensed Producers in Canada. The company utilizes toll processors in foreign countries to encapsulate and package its formulations that can be sold in traditional distribution channels and online.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
